
Opinion|Videos|December 20, 2024
Additional Toxicities in GPRC5D-Directed Bispecifics for RRMM
Author(s)Binod Dhakal, MD, MS
Panelist discusses how, based on the patient achieving sCR with emerging oral, skin, and nail toxicities, panelist would recommend initiating supportive care, including oral hygiene protocols, topical treatments, and prophylactic nail care. These toxicities are generally less severe than those of BCMA-targeted bispecifics, which often present with more systemic CRS and neurotoxicity.
Advertisement
Episodes in this series

Video content above is prompted by the following:
- After the first month of treatment, the patient achieved stringent complete response (sCR) but is experiencing the following symptoms: oral, skin, and nail toxicities.
- What mitigation strategies would you initiate for this patient?
- How do those toxicities compare with those of other bispecifics (ie, BCMA-directed) in this space?
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Reanalysis of Glioblastoma Vaccine Trial Suggests Larger Survival Benefit
2
FDA Accepts NDA for Mezigdomide Combination in Relapsed/Refractory Multiple Myeloma
3
What Long-Term Real-World Data on CAR T in Myeloma Could Reveal
4
Real-World Data Confirm Alectinib's Edge Over Crizotinib in ALK+ NSCLC
5































